Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Larkin Community Hospital
Age
18–90
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Adults of ages 18 to 90 years of both sexes
With positive SARS-CoV-2 carriage confirmed by nasopharyngeal PCR
Signed informed consent
1- Mild symptoms: Minimum respiratory symptoms or asymptomatic plus positive test
2- Moderate symptoms: Respiratory symptoms such as cough, mild shortness of breath with mild oxygen desaturation(room air SpO2 \<92% and \>88% or \<88% corrected to \>92% with 2lt of oxygen)
You may not be if
Patients with Severe symptoms: Hypoxia (SpO2 \<88% not corrected by 2 lt nc oxygen) plus severe shortness of breath (excluded)
Patient with very low viral load (threshold cycle \[Ct\] \> 25 per PCR).
Known hypersensitivity to one of the constituents, particularly to xylitol or GSE
Under 18 years of age
Women of childbearing age who are pregnant, breastfeeding mothers, and intend to become pregnant during the study period; unwilling/unable to take a pregnancy test.
Unable to provide informed consent or decline to consent or unwillingness to adhere to the Standard of Care protocol.
Patients with severe symptoms -Hypoxia (SpO2 \<88% not corrected by 2 liter non- concentrated oxygen) plus severe shortness of breath
History of immunodeficiency or are currently receiving immunosuppressive therapy.
Have had a planned surgical procedure within the past 12 weeks.
Already part of this trial, recruited at a different hospital.
Patient unable to perform oro-nasopharyngeal decolonization
Patients with acute exacerbation of severe comorbidities like heart disorders Chronic Obstructive Pulmonary Disease (COPD), Heart Failure New York Heart Association (NYHA) Class 3 and 4 and/or diseases with severe oxygenation problems
Patients on Remdesivir and/or other clinical trials.
Clareo Health | Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients
